List view / Grid view
Researchers have used computer modelling to find an existing investigational drug compound for leukaemia patients to treat triple negative breast cancer...
As the drug discovery industry takes on the complex disease states that plague our world, the need for more relevant and timely answers from cell-based assays has become a major challenge.
This recent webinar focused on the role of IntelliCyt’s iQue Screener PLUS platform as a high throughput suspension cell screening platform to facilitate simultaneous assessment of multiple parameters, while using minimal sample volumes.
Research shows that preventing or reversing ‘T-cell exhaustion’ with targeted therapies could enhance the effects of immunotherapy.
The Compendium provides scientists an online resource to help design efficient in vitro and in vivo oncology research studies.
While studying the complex correlation between tissue stiffness and breast cancer development, researchers found that cancer cells tend to become more aggressive when the surrounding tissue stiffens...
Researchers have identified a subset of T cells, whose frequency serves as early childhood immune signature that predicts the risk of developing asthma later on.
1 February 2018 | By PerkinElmer
This webinar discussed a screening assay that recapitulates the activation of ER stress sensor IRE1 and an assay to quantify cell migration phenotypes, as applied to cardiovascular target validation and drug discovery.
Scientists have rebuilt adenoviruses so that they effectively recognise and infect tumour cells.
A study has laid the groundwork for the use of PD-1 inhibitors with an aggressive form of brain cancer, namely supratentorial pediatric ependymoma.
Analysing individuals' genotypes and immunotypes could yield customised treatments for prostate cancer...
Johns Hopkins scientists have used a form of artificial intelligence to create a map that compares types of cellular receptors, the chemical ‘antennas’ on the surface of immune system T-cells.
4 January 2018 | By IntelliCyt Corporation
In this webinar, speakers discussed how the IntelliCyt iQue Screener Plus platform is being utilised to deliver rich datasets for compound screening, target validation and is how it is transforming immuno-oncology.
One of the biggest challenges facing drug discovery across all therapeutic modalities (small molecule, biologics, and cellular) remains the balance between physiological relevance and throughput.
A novel compound may restore immune response in patients with melanoma, according to a study presented at the ESMO Immuno Oncology Congress 2017.1
